The Diabetes Complications Biology Department at Hagedorn Research Institute consists of enthusiastic scientists, research technicians, post docs and PhD students.
We strive to generate future medications for treatment of diabetes associated complications (atherosclerosis, nephropathy, retinopathy). Our key hypothesis is that targeting specific parts of the vascular system can synergize with anti-diabetic therapeutics and reduce the manifestation of micro and macrovascular disease.
We identify and evaluate new biological targets and explore the assets of our existing peptide candidates. We are responsible for the initial R&D diabetes complication initiatives in Novo Nordisk Diabetes Research Unit. Both metabolic disease and inflammation are part of our scientific expertise. Our experimental expertise covers classical and novel in vitro models of type 2 diabetes and we work with e.g. vascular cells, immune cells and islets of Langerhans.
We collaborate with our research unit colleagues within pharmacology and peptide chemistry and non clinical development. In addition, we collaborate with a range of other areas within R&D, e.g. scientific intelligence, sourcing, patents, new product planning as well as local and international research institutions and scientific experts.
|
To identify and develop peptides, proteins or antibodies that targets Diabetes Complications (DC)
